Insulet Corporation (PODD) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Total Assets Chart for Insulet Corporation
Insulet Corporation (PODD) total assets for FY2025 were USD 3.2B, a 3.3% change from FY2024. Insulet Corporation's total assets grew from USD 17.5M in 2002 to USD 3.2B in 2025 (18119.4% over 23 years). Total assets compound annual growth rate: 5-year CAGR of 11.2%, 10-year CAGR of 27.8%, 20-year CAGR of 30.0%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $9.65B
- Implied Share Price
- $139.30
- Enterprise Value
- $9.63B
- Revenue (TTM)
- $3.05B
- EBITDA
- $614.40M
- Profit Margin
- 12.29%
- Trailing P/E
- 25.01
- Forward P/E
- 21.46
- Price/Book (MRQ)
- 6.48
- Price/Sales (TTM)
- 3.16
- EV/EBITDA
- 14.76
- EV/Revenue
- 3.16
- Dividend Yield
- —
- Book Value
- $20.52
- Free Cash Flow (FY2025)
- $377.70M
- Free Cash Flow Yield
- 3.91%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.